Clarifying debates about drug decriminalization Pharmaceutical & Drug Policy Clarifying debates about drug decriminalization Beau Kilmer June 24, 2026
Comments on biosimilar streamlining efforts and context on commercial barriers to competition Pharmaceutical & Drug Policy Comments on biosimilar streamlining efforts and context on commercial barriers to competition Ryan Conrad May 7, 2026
Rethinking Medicare’s bundled payment model for opioid treatment programs Pharmaceutical & Drug Policy Rethinking Medicare’s bundled payment model for opioid treatment programs Haiden A. Huskamp, Alisa B. Busch, Dominic Hodgkin, Christopher Tompkins, Richard G. Frank April 2, 2026
What earnings calls and SEC filings reveal about the state of pharma Pharmaceutical & Drug Policy What earnings calls and SEC filings reveal about the state of pharma Richard G. Frank March 31, 2026